COMPETING INTERESTS
TL has received grants from Gilead Sciences, has served as consultant to Gilead Sciences, Merck/MSD, Pfizer, Astellas, AstraZeneca and Roche, and served at the speaker´s bureau of Gilead Sciences, Merck/MSD, Astellas, Pfizer and GSK. AHG has received grants from Gilead, Merck, Sharp & Dohme and Pfizer and has served as consultant to Amplyx, Astellas, Basilea, F2G, Gilead. Merck, Sharp & Dohme, Pfizer, Scynexis, and Mundipharma. SC served at the speaker´s bureau of Gilead Sciences and Pfizer. AA has received honoraria for lectures, consultancy or advisory board participation from the following companies: Jazz Pharmaceuticals, Amgen, Novartis, MSD, Jazz Pharmaceuticals, Amgen, Novartis, MSD, and Gilead. He has received compensation for travel expenses from Jazz Pharmaceuticals. MS and/or study group have received research support from SHIRE, JazzPharma, Servier, SigmaTau, Amgen, and Novartis. MS has received honoraria from Servier, Novartis, and JazzPharma.